Fundz

Octave Bioscience Secures $32 Million Series B Financing

PRIVATEDec 17, 2020

Amount Raised

$32 Million

Round Type

Series B

Menlo ParkBiotechnologyHealthcare

Description

Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the completion of a $32 million Series B financing. Northpond Ventures led the investment round with participation by Deerfield Management and Casdin Capital. All previous investors participated in the financing round, including the Blue Venture Fund, Echo Health Ventures, Section 32 and several private investors. This financing will allow the company to complete development of its novel measurement and management products and services, further expand clinical data, initiate early commercial activities and begin to serve neurologists, MS patients and health plans.

Who to call at Octave Bioscience, and when

A new round usually means Octave Bioscience is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Octave Bioscience raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Octave Bioscience, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Octave Bioscience. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Octave Bioscience

Location

Menlo Park, California, United States

About

Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with the Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Octave Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsMelinda T., Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Octave Bioscience's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Octave Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.